Compare Intuitive Surgical, Inc. (ISRG) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Tilray Brands Inc — how do they compare? Intuitive Surgical, Inc. trades at $423.96 (market cap $146.76B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Intuitive Surgical, Inc. is far larger — about 276.6× Tilray Brands Inc's market cap, and Intuitive Surgical, Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Tilray Brands Inc for 31 Days on average.
| ISRG | TLRY | |
|---|---|---|
Market Cap | $146.76B | $530.54M |
Volume | 2,529,814 | 9,099,075 |
Sector | Health | Health |
52-Week High | $592.85 | $17.20 |
52-Week Low | $332.02 | $3.54 |
Typical Hold Time | 84 Days | 31 Days |
Enterprise Value | $141.54B | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $415.41, up 0.21% with a bullish technical outlook. The stock shows strong fundamentals with 2025 revenue of $10.06B and net income of $2.86B, maintaining consistent earnings beats. Valuation metrics remain elevated with a P/E of 47.64 and P/S of 13.54, reflecting premium pricing for the robotic surgery leader. Recent news highlights international expansion in India and Japan to offset China weakness, while da Vinci 5 upgrades and ASC market penetration drive growth.
ISRG presents a compelling growth story with dominant market position and expanding global footprint, though premium valuation requires sustained execution. Key risks include procedure growth moderation and competitive pressures. Analyst consensus remains strongly bullish with $480.78 price target representing 16% upside potential from current levels.
TLRY trades at $3.59, down 3.36% on the day and near 52-week lows, with a bearish technical signal. The company reported revenue of $821.31M for 2025 but posted a net loss of -$2.19B, missing earnings expectations for four consecutive quarters. While analyst consensus shows 70% hold ratings, the stock faces significant profitability challenges with negative margins and cash flow concerns despite some revenue growth projections.
The outlook remains challenging with persistent losses and negative cash flow, though the stock trades at discounted valuation multiples. Key risks include ongoing profitability struggles and cannabis regulatory uncertainty. Potential catalysts include upcoming Q1 2027 earnings on October 8, 2026, and potential marijuana reform developments that could benefit the company's positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
